Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial (FGISP-RCT)
Primary Purpose
Non-erosive Gastroesophageal Reflux Disease, Functional Dyspepsia, Irritable Bowel Syndrome
Status
Completed
Phase
Not Applicable
Locations
Hong Kong
Study Type
Interventional
Intervention
Counseling
Sponsored by
About this trial
This is an interventional health services research trial for Non-erosive Gastroesophageal Reflux Disease focused on measuring Functional gastrointestinal disorder, GERD, reflux, irritable bowel syndrome, Functional dyspepsia, postprandial fullness, counseling, service
Eligibility Criteria
Inclusion Criteria:
Present with symptoms suggestive of any of the following FGID according to Rome III Classification:
- Non-erosive gastroesophageal reflux disease (NERD) Weekly symptoms of heartburn or acid regurgitation of moderate severity for at least 6 months
- Functional dyspepsia (FD) Weekly symptoms of epigastric burning sensation, early satiety or postprandial fullness for at least 6 months
- Irritable bowel syndrome (IBS)
Symptoms of abdominal pain or discomfort of at least 3 times a month, in the last 6 months, associated with 2 or more of the following:
- Improvement with defecation
- Onset associated with a change in frequency of stool
- Onset associated with a change in form (appearance) of stool
Exclusion Criteria:
- Erosive esophagitis (Still eligible for IBS patients)
- Peptic ulcer (Still eligible for IBS patients after complete ulcer healing)
- H. pylori positive
- Organic causes of symptoms, including malignancy, abnormal thyroid function, and inflammatory bowel disease.
- Previous gastric surgery
- Pregnancy
- Illiterate
- Unable to sign the written consent form • Abdominal surgery within one year prior to joining the program
Sites / Locations
- Prince of Wales Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Counseling group
Control
Arm Description
Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician
Usual management in GI specialty clinic
Outcomes
Primary Outcome Measures
Self-efficacy and decrease in psychological distress measured by Health status and management scales and Patient Health Questionnaire (PHQ)
Rate of attendance to "on-demand follow up within 1 year" option given at Final visit
Secondary Outcome Measures
Frequency of doctor's visits
Use of emergency service
Self-rated health measured by Health status and management scales
Social/role activities limitation measured by Health status and management scales
Full Information
NCT ID
NCT01047800
First Posted
January 12, 2010
Last Updated
April 25, 2017
Sponsor
Chinese University of Hong Kong
1. Study Identification
Unique Protocol Identification Number
NCT01047800
Brief Title
Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial
Acronym
FGISP-RCT
Official Title
Effectiveness of Counseling for Functional Gastrointestinal Disorder Patients: A Double-blind Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
January 2010 (Actual)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
December 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Background:
Functional gastrointestinal disorder (FGID) is the most common gastrointestinal disease in daily clinical practice. The disease is symptomatic but has no identifiable cause by standard diagnostic tests such as endoscopy. It is characterized by its frequent relapses and thus the disease causes a significant level of stress and anxiety to patients. Due to the complexity and chronicity of the disease, it is believed that appropriate counseling on the nature and management of the disease is necessary to decrease patient's anxiety level and improve quality of life.
Indication:
Patients who have symptoms suggestive of FGID including non-erosive gastroesophageal reflux disease (NERD), functional dyspepsia (FD) or irritable bowel syndrome (IBS).
Aim:
To validate the effectiveness of counseling in patients suffering from FGID.
Method:
Patients recruited to the study will follow the usual management of patients attending the Gastroenterology specialty clinic in Prince of Wales Hospital. Standard blood tests and endoscopy will be performed. Standard medication will be given to the patients for 8 weeks after endoscopy and the patients will come back to the specialty clinic for a final visit.
The patient will be given an "on-demand follow up within 1 year" option at final visit. The patient will decide if he/she wants to come back to our specialty clinic to follow up his/her problem within one year.
Follow-up after Final Visit Follow-up questionnaires will be mailed to patients 6 months, 1 and 2 years after Final visit.
Randomization:
All the patients will be randomized into two groups in First Visit: 1) Control group, and 2) Counseling group. Both groups of patients will follow the above protocol, except that 2 extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician.
Detailed Description
Patients recruited to the study will follow the usual management of patients attending the Gastroenterology specialty clinic in Prince of Wales Hospital, along with the following protocol:
First Visit
Patient signs written consent
Attending physician manages patient as usual
Blood tests will be arranged for patient:
FD & NERD patients: CBC w/ differential count, LFT, TFT, random glucose
IBS patients: CBC w/ differential count, LFT, TFT, ESR, C-reactive protein
Patient completes questionnaires
Endoscopy Visit
Endoscopy examinations
FD & NERD patients: oesophagogastroduodenoscopy (OGD) with rapid urea test (RUT) and biopsy of antrum sample for histology to check h. pylori status
IBS patients: colonoscopy
If no organic causes are found to explain for FGI symptoms, the following standard medication will be prescribed for 8 weeks:
FD: Pantoprazole 40mg daily; GERD: Pantoprazole 40mg daily; IBS: Mebeverine 135mg tid PRN before meal, Loperamide 4mg tid PRN (for diarrhea), Metamucil 2 teaspoon bid (for constipation).
Final Visit (8 weeks after endoscopy visit)
Attending physician manages patient as usual
Printout of investigation (endoscopy, blood tests) reports given to patient
Patient completes questionnaires
The patient will be given an "on-demand follow up within 1 year" option at this visit. The patient will decide if he/she wants to come back to our specialty clinic to follow up his/her problem within one year. If the patient does not come back during this period, his/her case will be closed and a new referral will be required if he/she wants to be taken care by the specialty again.
Follow-up after Final Visit:
Follow-up questionnaires will be mailed to patients 6 months, 1 and 2 years after Final visit.
Randomization:
All the patients will be randomized into two groups in First Visit: 1) Control group, and 2) Counseling group. Both groups of patients will follow the above protocol, except that 2 extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician:
Counseling at first visit:
- Contents include: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions
Counseling at final visit:
- Contents include: prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions.
A research personnel who has been working with patients with FGID for at least one year will be responsible for the counseling service.
The random allocation sequence will be obtained from a computer-generated list of random numbers in blocks of 10 supplied by a trial statistician. Concealed allocation is achieved by an independent research staff who assigns intervention group according to consecutive numbers in sealed envelopes. The patients will be invited to participate in the study to assess 1 of 2 potentially helpful interventions. They will be explained that the relative effectiveness of both interventions are unproven and may or may not be beneficial.
In this study, the patients, attending physicians and endoscopes will all be blinded to the randomized arm that the patients are assigned to. The nature of the two arms will also be blinded to them. This arrangement is essential in clinical trials comparing different services or managing strategies and is clearly specified in the Patient Information Sheet.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-erosive Gastroesophageal Reflux Disease, Functional Dyspepsia, Irritable Bowel Syndrome
Keywords
Functional gastrointestinal disorder, GERD, reflux, irritable bowel syndrome, Functional dyspepsia, postprandial fullness, counseling, service
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Counseling group
Arm Type
Experimental
Arm Description
Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician
Arm Title
Control
Arm Type
No Intervention
Arm Description
Usual management in GI specialty clinic
Intervention Type
Behavioral
Intervention Name(s)
Counseling
Intervention Description
Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:
First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions
Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions.
Primary Outcome Measure Information:
Title
Self-efficacy and decrease in psychological distress measured by Health status and management scales and Patient Health Questionnaire (PHQ)
Time Frame
6 months after Final visit
Title
Rate of attendance to "on-demand follow up within 1 year" option given at Final visit
Time Frame
1 year after Final visit
Secondary Outcome Measure Information:
Title
Frequency of doctor's visits
Time Frame
1 and 2 years after Final visit
Title
Use of emergency service
Time Frame
1 and 2 years after Final visit
Title
Self-rated health measured by Health status and management scales
Time Frame
6 months, 1 and 2 years after Final visit
Title
Social/role activities limitation measured by Health status and management scales
Time Frame
6months, 1 and 2 years after Final visit
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Present with symptoms suggestive of any of the following FGID according to Rome III Classification:
Non-erosive gastroesophageal reflux disease (NERD) Weekly symptoms of heartburn or acid regurgitation of moderate severity for at least 6 months
Functional dyspepsia (FD) Weekly symptoms of epigastric burning sensation, early satiety or postprandial fullness for at least 6 months
Irritable bowel syndrome (IBS)
Symptoms of abdominal pain or discomfort of at least 3 times a month, in the last 6 months, associated with 2 or more of the following:
Improvement with defecation
Onset associated with a change in frequency of stool
Onset associated with a change in form (appearance) of stool
Exclusion Criteria:
Erosive esophagitis (Still eligible for IBS patients)
Peptic ulcer (Still eligible for IBS patients after complete ulcer healing)
H. pylori positive
Organic causes of symptoms, including malignancy, abnormal thyroid function, and inflammatory bowel disease.
Previous gastric surgery
Pregnancy
Illiterate
Unable to sign the written consent form • Abdominal surgery within one year prior to joining the program
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Justin C.Y. Wu, MBChB(CUHK)
Organizational Affiliation
Chinese University of Hong Kong
Official's Role
Principal Investigator
Facility Information:
Facility Name
Prince of Wales Hospital
City
Hong Kong
Country
Hong Kong
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial
We'll reach out to this number within 24 hrs